用重组活化凝血因子VII治疗一名胎儿死亡患者羊水栓塞临床表现为弥散性血管内凝血的情况。
Factor VIIa treatment of DIC as a clinical manifestation of amniotic fluid embolism in a patient with fetal demise.
作者信息
Kahyaoglu Inci, Kahyaoglu Serkan, Mollamahmutoglu Leyla
机构信息
Department of High Risk Pregnancies, Zekai Tahir Burak Women's Health and Education Hospital, Ankara, Turkey.
出版信息
Arch Gynecol Obstet. 2009 Jul;280(1):127-9. doi: 10.1007/s00404-008-0857-3. Epub 2008 Dec 2.
INTRODUCTION
A pregnant patient, with term intrauterine fetal demise, who developed cardiopulmonary arrest during labor, followed by disseminated intravascular coagulation (DIC) secondary to amniotic fluid embolism (AFE) that was treated with Recombinant Factor VIIa, is presented.
CASE REPORT
A 22-year-old Turkish woman was admitted to our antenatal clinic at 39 weeks 6 days of gestation with a complaint of decreased fetal movements for the previous 3 days. Shortly after presentation, she was noted to have circumoral cyanosis with shortness of breath and sudden loss of consciousness. After a 3,220 g macerated male fetus was delivered, persistent bleeding occurred in the mother and was managed with Recombinant Factor VIIa at a dose of 90 mcg/kg. She died 8 days after the admission due to multiple organ failure.
CONCLUSION
Recombinant Factor VIIa may be a treatment option for hemorrhage in patients with DIC related to AFE.
引言
本文介绍了一名足月宫内胎儿死亡的孕妇，其在分娩过程中发生心肺骤停，继发羊水栓塞（AFE）导致弥散性血管内凝血（DIC），随后接受重组凝血因子VIIa治疗。
病例报告
一名22岁的土耳其女性在妊娠39周6天时因前3天胎动减少入住我们的产前诊所。就诊后不久，她出现口周发绀、呼吸急促和突然意识丧失。在娩出一个体重3220克的浸软男胎后，母亲持续出血，接受了剂量为90微克/千克的重组凝血因子VIIa治疗。她在入院8天后因多器官衰竭死亡。
结论
重组凝血因子VIIa可能是治疗与AFE相关的DIC患者出血的一种选择。
Zotero 插件